ANTIBACTERIAL DRUG RESISTANCE MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-147683 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Antibacterial Drug Resistance Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET

7.1 GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA ANTIBACTERIAL DRUG RESISTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Melinta Therapeutics

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Allergan

16.3 Merck

16.4 Abbott Laboratories

16.5 Pfizer

16.6 GSK

16.7 PENDOPHARM

16.8 Absynth Biologics

16.9 Achaogen

16.10 Acino Holdings

16.11 Aventis Pharma

16.12 Austell Laboratories

16.13 Assembly Biosciences

16.14 Arpida,

16.15 Demuris

16.16 Evolva Holding

16.17 ContraFect

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS.

By Application
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)

Companies

Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida,
Demuris
Evolva Holding
ContraFect

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.